Promising Phase 2 Results and Strong Safety Profile Support Buy Recommendation for Atossa Therapeutics

TipRanksNov 4 09:45 ET

Atossa Repots Topline Data From the KARISMA-Endoxifen Phase 2 Study

TipRanksNov 4 06:41 ET

Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:

GlobeNewswireNov 4 06:30 ET

Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $4

Moomoo NewsNov 1 15:31 ET · Ratings

H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $6

Moomoo NewsOct 31 10:31 ET · Ratings

Express News | Atossa - (Z)-Endoxifen at 10 Mg Once Daily Met Primary Endpoint With 19/20 (95%) Receiving > 75 % of Planned Treatment in I-Spy-2 Phase 2 Trial

ReutersOct 31 08:15 ET